SDCC at ADA 2018

Presentations from SDCC


1. Should Patients with Microalbuminuria and Normal Blood Pressure be Treated with Renin Angiotensin Aldosterone System Blockade? —Yes, All Patients Should be Treated 
Peter Rossing.

2. Personalized Approach Based on Patient Characteristics and comorbidities
Peter Rossing.

3. Management of Patients with Type 2 Diabetes Shared between a Specialized Outpatient Clinic and Primary Health Care is Non-Inferior to Mono Management in a Specialized Outpatient Clinic - a Prospective, Randomized, Non-Inferiority Trial
Lene Munch, Birgitte Bennich, Dorthe Overgaard, Hanne Konradsen, Helle Middelfart, Niels Kaarsberg, Filip K. Knop, Tina Vilsbøll and Michael E. Røder


4. Postprandial Effects of Individual and Combined GIP and GLP-1 Receptor Antagonization in Healthy Subjects
Lærke Smidt Gasbjerg, Mads Marstrand Helsted, Alexander Hovard Sparre-Ulrich, Amalie Rasmussen Lanng, Signe Stensen, Mette Høy Jakobsen, Bolette Hartmann, Mikkel Bring Christensen, Jens Juul Holst, Tina Vilsbøll, Mette Marie Rosenkilde, Filip Krag Knop

5. Glucagon Resistance at the Level of Amino Acid Turnover and Ureagenesis in Obese Subjects with Hepatic Steatosis
Malte P. Suppli, Jonatan I. Bagger, Asger Lund, Nicolai J. Wewer. Albrechtsen, Jens J. Holst, Tina Vilsbøll and Filip K. Knop

6. More subjects achieved composite reductions of ≥1% HbA1c, ≥5% body weight and ≥5 mmHg SBP with semaglutide vs comparators (SUSTAIN 1–5, 7)
Kathleen Dungan, Vanita R Aroda, Filip Krag Knop, Lawrence A Leiter, Nanna Leonora Lausvig, Søren Lindberg, Juris Meier

7. Dapagliflozin Plus Saxagliptin Shows Non-Inferior A1C Reduction vs Insulin Glargine in Patients with Type 2 Diabetes Inadequately. Controlled by Metformin with or without Sulfonylurea
Tina Vilsbøll, Ella Ekholm, Eva K Johnsson, Nalina Dronamraju, Serge Jabbour, Marcus Lund, Copenhagen, Denmark, Mölndal, Sweden, Gaithersburg, MD, Philadelphia, PA, Gothenburg, Sweden

8. Semaglutide treatment and renal function in the Sustain 6 trial
Tina Vilsbøll, Janusz Gumprecht, Robert Silver, Thomas Hansen, Jonas Pettersson, John Wilding

9. Data Pipeline for Clinical Diabetes Metabolomics – From Targeted Mass-Spectra to Patient Stratification
Tommi Suvitaival, Linda Ahonen, Ashfaq Ali, Cristina Legido Quigley, Lars Ove Dragsted, Peter Rossing.


1.Do Greenlandic Carriers of the TBC1D4 p.Arg684Ter Variant Have Increased Risk of Cardiovascular Disease?
Marit Eika Jørgensen

2. The Role of Glucagon-Like Peptide-1 for the Postprandial Effects of Metformin in Type 2 Diabetes
Laura S. Hansen, Lærke S. Gasbjerg, Andreas Brønden, Niels B. Dalsgaard, Emilie Bahne, Pernille H. Sørensen, Jens J. Holst, Tina Vilsbøll, Filip K. Knop

3. Mono- and co-activation of the GIP and GLP-1 receptors inhibits bone resorption
N.C. Bergmann, A. Lund, S.M. Heimbürger, N.R. Jørgensen, L. Jessen, M.B. Christensen, T. Vilsbøll, F.K. Knop

4.Glucagon-like peptide 1 is a Major Determinant of the Second-meal Effect in Patients with Type 2 Diabetes

Sigrid Bergmann, Natasha C. Bergmann, Lærke S. Gasbjerg, Jens J. Holst, Tina Villsbøl and Filip K. Knop

5. Individual and Combined Glucose-Lowering Effects of Glucagon Receptor Antagonism and Sodium-Glucose Cotransporter 2 inhibition

Sofie Hædersdal, Asger Lund, Henrik E.G. Maagensen, Elisabeth Nielsen-Hannerup, Jens J. Holst, Filip K. Knop Tina Vilsbøll

6. Diabetes Distress and Glycemic Control in Working People with Type 1 Diabetes—The Role of Intentional Hyperglycemia at Work*

Ulla Møller Hansen, Timothy Skinner, Kasper Olesen, Ingrid Willaing.

8. Exploring Psychological Aspects Of Hyperglycemia In People With Type 2 Diabetes

Mette A. Nexo, Bryan Cleal, Ingrid Willaing.

9. Empowerment, Motivation and Medical Adherence (EMMA): Results of an RCT in Patients with Poorly Regulated Type 2 Diabetes
Annemarie R. Varming, Kasper Olesen, Ingrid Willaing.   

10. From research to action – impactful intervention arenas

D. Napier, N. Lund, M. Bagger, B.B. Jensen

11. How Does Risk Screening for Kidney Disease Influence Diabetes Distress?
Lene Eide Joensen, Kristoffer Panduro Madsen, Marie Frimodt-Møller, Nete Tofte, Ingrid Willaing, Morten Kofod Lindhardt, Peter Rossing.   

12. C-Peptide Levels Are Associated with Glycemic Variability and Hypoglycemia in Insulin-Treated Type 2 Diabetes

Merete Bechmann Christensen, Kirsten Nørgaard.


1.A Collaborative Approach To Health Promotion Targeting People With Mental Illness At Risk Of Diabetes: A Process Evaluation
Nana Folmann Hempler, Regitze Anne Saurbrey Pals, Sabina Drejer, Rikke Hjort Laursen, Lone Oest, Vinie Diana Hvidbak Levisen,Naja Ramskov Krogh.

2.The Effect of Ethanol on Inflammation Markers and FGF-21 in Healthy Individuals
Lanng AR,  Gasbjerg LS, Bergmann NC, Møller HJ4 Gillum MP, Grønbæk H, Vilsbøll T, Knop FK

Responsible editor